What’s next after immunotherapy? The rise of oncolytic virus treatments

In the last decade, immunotherapy has revolutionized cancer care. By harnessing the body’s own immune system to recognize and attack tumors, therapies like checkpoint inhibitors and CAR-T cells have extended lives and offered new hope, particularly for patients with advanced-stage cancers. Yet despite its breakthroughs, immunotherapy doesn’t work for everyone. Some cancers remain resistant. Others adapt. In this space between success and shortfall, researchers are asking: what’s next?

The answer may lie in a fascinating new frontier—oncolytic virus therapy, an approach that merges virology and oncology in an effort to kill tumors from the inside out.

How Oncolytic Viruses Work

At its core, oncolytic virus therapy uses viruses engineered (or selected) to infect and destroy cancer cells while sparing healthy tissue. These viruses do more than just replicate inside the tumor until it bursts. They can also expose cancer antigens to the immune system, triggering a broader and more lasting immune attack.

Unlike traditional immunotherapies that aim to stimulate the immune system directly, oncolytic viruses prime it by creating a scene of destruction within the tumor itself. This localized chaos alerts immune cells to the cancer’s presence, making it harder for tumors to hide.

The process unfolds in three key steps:

• Selective infection: The virus is attracted to or better tolerated by tumor cells, sparing normal tissue.
• Viral replication and lysis: Once inside, it replicates until the tumor cell bursts.
• Immune activation: The destroyed cancer cell releases tumor antigens, attracting immune cells to join the fight.

This dual mode of action—direct tumor destruction plus immune stimulation—sets oncolytic therapy apart from both chemotherapy and first-generation immunotherapies.

Clinical Milestones and Promising Results

The most well-known example to date is Talimogene laherparepvec (T-VEC), a modified herpes simplex virus approved by the FDA in 2015 for advanced melanoma. It was the first oncolytic virus approved in the United States, showing that this approach could move beyond theory into clinical reality.

Since then, clinical trials have expanded to other cancers—glioblastoma, pancreatic, colorectal, prostate, and triple-negative breast cancer, to name a few. Some trials pair oncolytic viruses with checkpoint inhibitors, seeking a synergistic effect. Others are testing custom viruses that deliver immune-modulating genes directly into the tumor microenvironment.

While still early in development, recent results have shown encouraging signs of tumor shrinkage, prolonged survival, and even systemic responses beyond the injection site—suggesting the immune system is indeed getting involved.

Challenges and the Path Ahead

Despite the excitement, oncolytic virotherapy faces significant challenges before it can become a standard cancer treatment:

• Delivery remains difficult: Many therapies require direct injection into the tumor, limiting use to accessible sites.
• The immune system may work too well: Pre-existing immunity to certain viruses can prevent them from reaching their target.
• Tumor microenvironments can resist invasion: Dense tissue or suppressive cells around the tumor can block viral spread.
• Safety must be ensured: Although engineered for safety, viruses must still be monitored closely, especially in immunocompromised patients.

To address these hurdles, researchers are exploring capsule delivery systems, systemic infusion with shielding, and next-generation viruses that can evade neutralizing antibodies or self-destruct after completing their task. There’s also growing interest in personalized virotherapy—using a patient’s tumor profile to design or select the most effective viral strategy.

Looking to the Future: A New Partner in Cancer Therapy

Oncolytic virus therapy isn’t expected to replace immunotherapy or chemotherapy overnight. Instead, it may augment existing treatments, filling the gaps where current options fall short. With more clinical trials, better viral designs, and improved delivery systems, this approach could eventually become a cornerstone of combination cancer therapy.

It also represents a philosophical shift: using something once feared—a virus—as a therapeutic ally. This inversion of threat into treatment speaks to the elegance and adaptability of modern oncology.

The road ahead will be complex, but the potential is vast. For patients with cancers that resist today’s best tools, oncolytic viruses could represent not just another option—but a new beginning in the ongoing evolution of cancer care.